Skip to main content
Erschienen in: Clinical and Experimental Nephrology 10/2019

13.07.2019 | Original article

Dynamic variation of kidney injury molecule-1 mRNA and protein expression in blood and urine of renal transplant recipients: a cohort study

verfasst von: Sanaz Keshavarz Shahbaz, Fatemeh Pourrezagholi, Mohesn Nafar, Pedram Ahmadpoor, Mehri Barabadi, Farshad Foroughi, Morteza Hosseinzadeh, Mir Saeed Yekaninejad, Aliakbar Amirzargar

Erschienen in: Clinical and Experimental Nephrology | Ausgabe 10/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Acute renal dysfunction still constitutes a highly significant obstacle to renal transplantation outcome. Kidney injury molecule-1 is highly upregulated in proximal tubular cells and shed into the urine and blood circulation following kidney injury. The aim of current cohort study was to evaluate the urine KIM-1 (uKIM-1) mRNA expression level and its protein concentration in blood and urine samples to determine whether sequential monitoring of KIM-1 in renal allograft recipients is a reliable biomarker for predicting the clinical status and outcome.

Methods

Both uKIM-1 mRNA expression level and the level of serum and uKIM-1 protein concentration in the 52 renal transplant recipients were respectively quantified using real-time PCR and ELISA methods at 2, 90 and 180 days after transplantation.

Result

KIM-1 mRNA and protein expression level in the blood and urine samples of patients with graft dysfunction was significantly higher than patients with well-functioning graft on days 2, 90 and 180 after transplantation. Receiver-operating characteristic curve analysis of mRNA and protein expression levels showed that urinary and blood KIM-1 at months 3 and 6 could predict acute renal dysfunction at 6 months and 1 year after transplantation.

Conclusion

Sequential monitoring of uKIM-1 mRNA expression level and its protein concentration in the serum and urine samples of renal transplant patients suggests that KIM-1 could be a sensitive and specific biomarker for early diagnosis and prognosis of kidney allograft injury.
Literatur
1.
Zurück zum Zitat Hariharan S, et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med. 2000;342(9):605–12.CrossRefPubMed Hariharan S, et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med. 2000;342(9):605–12.CrossRefPubMed
2.
Zurück zum Zitat Tonelli M, et al. Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes. Am J Transplant. 2011;11(10):2093–109.CrossRefPubMed Tonelli M, et al. Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes. Am J Transplant. 2011;11(10):2093–109.CrossRefPubMed
3.
Zurück zum Zitat Langone AJ, Chuang P. The management of the failed renal allograft: an enigma with potential consequences. In: Seminars in dialysis. Hoboken: Wiley Online Library; 2005. Langone AJ, Chuang P. The management of the failed renal allograft: an enigma with potential consequences. In: Seminars in dialysis. Hoboken: Wiley Online Library; 2005.
4.
Zurück zum Zitat Solez K, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant. 2008;8(4):753–60.CrossRefPubMed Solez K, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant. 2008;8(4):753–60.CrossRefPubMed
5.
Zurück zum Zitat Fidler ME, et al. Histologic findings of antibody-mediated rejection in ABO blood-group-incompatible living-donor kidney transplantation. Am J Transplant. 2004;4(1):101–7.CrossRefPubMed Fidler ME, et al. Histologic findings of antibody-mediated rejection in ABO blood-group-incompatible living-donor kidney transplantation. Am J Transplant. 2004;4(1):101–7.CrossRefPubMed
6.
Zurück zum Zitat Ushigome H, et al. Findings of graft biopsy specimens within 90 days after ABO blood group incompatible living donor kidney transplantation compared with ABO-identical and non-identical transplantation. Clin Transplant. 2010;24:16–211.CrossRefPubMed Ushigome H, et al. Findings of graft biopsy specimens within 90 days after ABO blood group incompatible living donor kidney transplantation compared with ABO-identical and non-identical transplantation. Clin Transplant. 2010;24:16–211.CrossRefPubMed
7.
Zurück zum Zitat Toki D, et al. Acute antibody-mediated rejection in living ABO-incompatible kidney transplantation: long-term impact and risk factors. Am J Transplant. 2009;9(3):567–77.CrossRefPubMed Toki D, et al. Acute antibody-mediated rejection in living ABO-incompatible kidney transplantation: long-term impact and risk factors. Am J Transplant. 2009;9(3):567–77.CrossRefPubMed
8.
9.
Zurück zum Zitat Ichimura T, et al. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J Biol Chem. 1998;273(7):4135–42.CrossRefPubMed Ichimura T, et al. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J Biol Chem. 1998;273(7):4135–42.CrossRefPubMed
10.
Zurück zum Zitat Han WK, et al. Kidney injury molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int. 2002;62(1):237–44.CrossRefPubMed Han WK, et al. Kidney injury molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int. 2002;62(1):237–44.CrossRefPubMed
11.
Zurück zum Zitat Bonventre JV. Kidney injury molecule-1 (KIM-1): a specific and sensitive biomarker of kidney injury. Scand J Clin Lab Investig. 2008;68(sup241):78–83.CrossRef Bonventre JV. Kidney injury molecule-1 (KIM-1): a specific and sensitive biomarker of kidney injury. Scand J Clin Lab Investig. 2008;68(sup241):78–83.CrossRef
12.
Zurück zum Zitat Vaidya VS, et al. Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury. Am J Physiol Ren Physiol. 2006;290(2):F517–F529529.CrossRef Vaidya VS, et al. Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury. Am J Physiol Ren Physiol. 2006;290(2):F517–F529529.CrossRef
13.
Zurück zum Zitat van Timmeren MM, et al. Tubular kidney injury molecule-1 in protein-overload nephropathy. Am J Physiol Ren Physiol. 2006;291(2):F456–F464464.CrossRef van Timmeren MM, et al. Tubular kidney injury molecule-1 in protein-overload nephropathy. Am J Physiol Ren Physiol. 2006;291(2):F456–F464464.CrossRef
15.
Zurück zum Zitat Umetsu SE, et al. TIM-1 induces T cell activation and inhibits the development of peripheral tolerance. Nat Immunol. 2005;6(5):447.CrossRefPubMed Umetsu SE, et al. TIM-1 induces T cell activation and inhibits the development of peripheral tolerance. Nat Immunol. 2005;6(5):447.CrossRefPubMed
16.
Zurück zum Zitat Monney L, et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature. 2002;415(6871):536–41.CrossRefPubMed Monney L, et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature. 2002;415(6871):536–41.CrossRefPubMed
17.
Zurück zum Zitat Kuchroo VK, et al. The TIM gene family: emerging roles in immunity and disease. Nat Rev Immunol. 2003;3(6):454–63.CrossRefPubMed Kuchroo VK, et al. The TIM gene family: emerging roles in immunity and disease. Nat Rev Immunol. 2003;3(6):454–63.CrossRefPubMed
18.
Zurück zum Zitat Meyers JH, et al. TIM-4 is the ligand for TIM-1, and the TIM-1–TIM-4 interaction regulates T cell proliferation. Nat Immunol. 2005;6(5):455.CrossRefPubMed Meyers JH, et al. TIM-4 is the ligand for TIM-1, and the TIM-1–TIM-4 interaction regulates T cell proliferation. Nat Immunol. 2005;6(5):455.CrossRefPubMed
20.
Zurück zum Zitat van Timmeren MM, et al. Tubular kidney injury molecule-1 (KIM-1) in human renal disease. J Pathol. 2007;212(2):209–17.CrossRefPubMed van Timmeren MM, et al. Tubular kidney injury molecule-1 (KIM-1) in human renal disease. J Pathol. 2007;212(2):209–17.CrossRefPubMed
21.
Zurück zum Zitat Vaidya VS, et al. Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies. Nat Biotechnol. 2010;28(5):478–85.CrossRefPubMedPubMedCentral Vaidya VS, et al. Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies. Nat Biotechnol. 2010;28(5):478–85.CrossRefPubMedPubMedCentral
22.
23.
24.
Zurück zum Zitat Sabbisetti VS, et al. Blood kidney injury molecule-1 is a biomarker of acute and chronic kidney injury and predicts progression to ESRD in type I diabetes. J Am Soc Nephrol. 2014;25(10):2177–86.CrossRefPubMedPubMedCentral Sabbisetti VS, et al. Blood kidney injury molecule-1 is a biomarker of acute and chronic kidney injury and predicts progression to ESRD in type I diabetes. J Am Soc Nephrol. 2014;25(10):2177–86.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Jin Z-K, et al. Kidney injury molecule-1 and osteopontin: new markers for prediction of early kidney transplant rejection. Mol Immunol. 2013;54(3):457–64.CrossRefPubMed Jin Z-K, et al. Kidney injury molecule-1 and osteopontin: new markers for prediction of early kidney transplant rejection. Mol Immunol. 2013;54(3):457–64.CrossRefPubMed
26.
Zurück zum Zitat Dieterle F, et al. Renal biomarker qualification submission: a dialog between the FDA-EMEA and predictive safety testing consortium. Nat Biotechnol. 2010;28(5):455–62.CrossRefPubMed Dieterle F, et al. Renal biomarker qualification submission: a dialog between the FDA-EMEA and predictive safety testing consortium. Nat Biotechnol. 2010;28(5):455–62.CrossRefPubMed
27.
Zurück zum Zitat Food U, Administration D. FDA, European Medicines Agency to consider additional test results when assessing new drug safety: Collaborative effort by FDA and EMEA expected to yield additional safety data. 2008. 2014. Food U, Administration D. FDA, European Medicines Agency to consider additional test results when assessing new drug safety: Collaborative effort by FDA and EMEA expected to yield additional safety data. 2008. 2014.
28.
Zurück zum Zitat Zhang P, et al. Kidney injury molecule-1 expression in transplant biopsies is a sensitive measure of cell injury. Kidney Int. 2008;73(5):608–14.CrossRefPubMed Zhang P, et al. Kidney injury molecule-1 expression in transplant biopsies is a sensitive measure of cell injury. Kidney Int. 2008;73(5):608–14.CrossRefPubMed
29.
Zurück zum Zitat Van Timmeren MM, et al. High urinary excretion of kidney injury molecule-1 is an independent predictor of graft loss in renal transplant recipients. Transplantation. 2007;84(12):1625.CrossRefPubMedPubMedCentral Van Timmeren MM, et al. High urinary excretion of kidney injury molecule-1 is an independent predictor of graft loss in renal transplant recipients. Transplantation. 2007;84(12):1625.CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Han WK, et al. Urinary biomarkers in the early detection of acute kidney injury after cardiac surgery. Clin J Am Soc Nephrol. 2009;4(5):873–82.CrossRefPubMedPubMedCentral Han WK, et al. Urinary biomarkers in the early detection of acute kidney injury after cardiac surgery. Clin J Am Soc Nephrol. 2009;4(5):873–82.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Renesto P, et al. High expression of Tim-3 mRNA in urinary cells from kidney transplant recipients with acute rejection. Am J Transplant. 2007;7(6):1661–5.CrossRefPubMed Renesto P, et al. High expression of Tim-3 mRNA in urinary cells from kidney transplant recipients with acute rejection. Am J Transplant. 2007;7(6):1661–5.CrossRefPubMed
32.
Zurück zum Zitat Lachenbruch PA, et al. Biomarkers and surrogate endpoints in renal transplantation: present status and considerations for clinical trial design. Am J Transplant. 2004;4(4):451–7.CrossRefPubMed Lachenbruch PA, et al. Biomarkers and surrogate endpoints in renal transplantation: present status and considerations for clinical trial design. Am J Transplant. 2004;4(4):451–7.CrossRefPubMed
33.
Zurück zum Zitat Kaplan B, Meier-Kriesche HU. Poor predictive value of serum creatinine for renal allograft loss. Am J Transplant. 2003;3(12):1560–5.CrossRefPubMed Kaplan B, Meier-Kriesche HU. Poor predictive value of serum creatinine for renal allograft loss. Am J Transplant. 2003;3(12):1560–5.CrossRefPubMed
34.
Zurück zum Zitat Kasiske BL, Andany MA, Danielson B. A thirty percent chronic decline in inverse serum creatinine is an excellent predictor of late renal allograft failure. Am J Kidney Dis. 2002;39(4):762–8.CrossRefPubMed Kasiske BL, Andany MA, Danielson B. A thirty percent chronic decline in inverse serum creatinine is an excellent predictor of late renal allograft failure. Am J Kidney Dis. 2002;39(4):762–8.CrossRefPubMed
35.
Zurück zum Zitat Roodnat J, et al. Proteinuria after renal transplantation affects not only graft survival but also patient survival. Transplantation. 2001;72(3):438–44.CrossRefPubMed Roodnat J, et al. Proteinuria after renal transplantation affects not only graft survival but also patient survival. Transplantation. 2001;72(3):438–44.CrossRefPubMed
36.
Zurück zum Zitat Devarajan P. Emerging biomarkers of acute kidney injury. In: Acute kidney injury. Basel: Karger Publishers; 2007. pp. 203–212. Devarajan P. Emerging biomarkers of acute kidney injury. In: Acute kidney injury. Basel: Karger Publishers; 2007. pp. 203–212.
37.
Zurück zum Zitat Sorof JM, et al. Histopathological concordance of paired renal allograft biopsy cores: effect on the diagnosis and management of acute rejection. Transplantation. 1995;60(11):1215–9.CrossRefPubMed Sorof JM, et al. Histopathological concordance of paired renal allograft biopsy cores: effect on the diagnosis and management of acute rejection. Transplantation. 1995;60(11):1215–9.CrossRefPubMed
38.
Zurück zum Zitat Furness PN, Taub N, Convergence of European Renal Transplant Pathology Assessment Procedures. International variation in the interpretation of renal transplant biopsies: report of the CERTPAP Project. Kidney Int. 2001;60(5):1998–2012.CrossRefPubMed Furness PN, Taub N, Convergence of European Renal Transplant Pathology Assessment Procedures. International variation in the interpretation of renal transplant biopsies: report of the CERTPAP Project. Kidney Int. 2001;60(5):1998–2012.CrossRefPubMed
39.
Zurück zum Zitat Anglicheau D, Suthanthiran M. Noninvasive prediction of organ graft rejection and outcome using gene expression patterns. Transplantation. 2008;86(2):192.CrossRefPubMedPubMedCentral Anglicheau D, Suthanthiran M. Noninvasive prediction of organ graft rejection and outcome using gene expression patterns. Transplantation. 2008;86(2):192.CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Hubank M, Schatz D. Identifying differences in mRNA expression by representational difference analysis of cDNA. Nucleic Acids Res. 1994;22(25):5640–8.CrossRefPubMedPubMedCentral Hubank M, Schatz D. Identifying differences in mRNA expression by representational difference analysis of cDNA. Nucleic Acids Res. 1994;22(25):5640–8.CrossRefPubMedPubMedCentral
41.
Zurück zum Zitat Ichimura T, et al. Kidney injury molecule-1 is a phosphatidylserine receptor that confers a phagocytic phenotype on epithelial cells. J Clin Investig. 2008;118(5):1657.CrossRefPubMed Ichimura T, et al. Kidney injury molecule-1 is a phosphatidylserine receptor that confers a phagocytic phenotype on epithelial cells. J Clin Investig. 2008;118(5):1657.CrossRefPubMed
42.
Zurück zum Zitat Savill J, Fadok V. Corpse clearance defines the meaning of cell death. Nature. 2000;407(6805):784–8.CrossRefPubMed Savill J, Fadok V. Corpse clearance defines the meaning of cell death. Nature. 2000;407(6805):784–8.CrossRefPubMed
43.
Zurück zum Zitat Zhang Z, Humphreys BD, Bonventre JV. Shedding of the urinary biomarker kidney injury molecule-1 (KIM-1) is regulated by MAP kinases and juxtamembrane region. J Am Soc Nephrol. 2007;18(10):2704–14.CrossRefPubMed Zhang Z, Humphreys BD, Bonventre JV. Shedding of the urinary biomarker kidney injury molecule-1 (KIM-1) is regulated by MAP kinases and juxtamembrane region. J Am Soc Nephrol. 2007;18(10):2704–14.CrossRefPubMed
44.
Zurück zum Zitat Bailly V, et al. Shedding of kidney injury molecule-1, a putative adhesion protein involved in renal regeneration. J Biol Chem. 2002;277(42):39739–48.CrossRefPubMed Bailly V, et al. Shedding of kidney injury molecule-1, a putative adhesion protein involved in renal regeneration. J Biol Chem. 2002;277(42):39739–48.CrossRefPubMed
45.
Zurück zum Zitat Ichimura T, et al. Kidney injury molecule-1: a tissue and urinary biomarker for nephrotoxicant-induced renal injury. Am J Physiol Ren Physiol. 2004;286(3):F552–F56363.CrossRef Ichimura T, et al. Kidney injury molecule-1: a tissue and urinary biomarker for nephrotoxicant-induced renal injury. Am J Physiol Ren Physiol. 2004;286(3):F552–F56363.CrossRef
46.
Zurück zum Zitat Han WK, et al. Human kidney injury molecule-1 is a tissue and urinary tumor marker of renal cell carcinoma. J Am Soc Nephrol. 2005;16(4):1126–34.CrossRefPubMedPubMedCentral Han WK, et al. Human kidney injury molecule-1 is a tissue and urinary tumor marker of renal cell carcinoma. J Am Soc Nephrol. 2005;16(4):1126–34.CrossRefPubMedPubMedCentral
47.
Zurück zum Zitat Myers BD, et al. Transtubular leakage of glomerular filtrate in human acute renal failure. Am J Physiol Ren Physiol. 1979;237(4):F319–F325325.CrossRef Myers BD, et al. Transtubular leakage of glomerular filtrate in human acute renal failure. Am J Physiol Ren Physiol. 1979;237(4):F319–F325325.CrossRef
48.
Zurück zum Zitat Sutton TA. Alteration of microvascular permeability in acute kidney injury. Microvasc Res. 2009;77(1):4–7.CrossRefPubMed Sutton TA. Alteration of microvascular permeability in acute kidney injury. Microvasc Res. 2009;77(1):4–7.CrossRefPubMed
49.
Zurück zum Zitat Sutton TA, Fisher CJ, Molitoris BA. Microvascular endothelial injury and dysfunction during ischemic acute renal failure. Kidney Int. 2002;62(5):1539–49.CrossRefPubMed Sutton TA, Fisher CJ, Molitoris BA. Microvascular endothelial injury and dysfunction during ischemic acute renal failure. Kidney Int. 2002;62(5):1539–49.CrossRefPubMed
50.
Zurück zum Zitat Nogare A, et al. Noninvasive analyses of kidney injury molecule-1 messenger RNA in kidney transplant recipients with graft dysfunction. In: Transplantation proceedings. Amsterdam: Elsevier; 2012. Nogare A, et al. Noninvasive analyses of kidney injury molecule-1 messenger RNA in kidney transplant recipients with graft dysfunction. In: Transplantation proceedings. Amsterdam: Elsevier; 2012.
51.
Zurück zum Zitat Shahbaz SK, et al. High expression of TIM-3 and KIM-1 in blood and urine of renal allograft rejection patients. Transpl Immunol. 2017;43:11–20.CrossRefPubMed Shahbaz SK, et al. High expression of TIM-3 and KIM-1 in blood and urine of renal allograft rejection patients. Transpl Immunol. 2017;43:11–20.CrossRefPubMed
52.
Zurück zum Zitat Liangos O, et al. Urinary N-acetyl-β-(d)-glucosaminidase activity and kidney injury molecule-1 level are associated with adverse outcomes in acute renal failure. J Am Soc Nephrol. 2007;18(3):904–12.CrossRefPubMed Liangos O, et al. Urinary N-acetyl-β-(d)-glucosaminidase activity and kidney injury molecule-1 level are associated with adverse outcomes in acute renal failure. J Am Soc Nephrol. 2007;18(3):904–12.CrossRefPubMed
53.
Zurück zum Zitat Malyszko J, et al. Kidney injury molecule-1 correlates with kidney function in renal allograft recipients. In: Transplantation proceedings. Amsterdam: Elsevier; 2010. Malyszko J, et al. Kidney injury molecule-1 correlates with kidney function in renal allograft recipients. In: Transplantation proceedings. Amsterdam: Elsevier; 2010.
54.
Zurück zum Zitat Tu Y, et al. Urinary netrin-1 and KIM-1 as early biomarkers for septic acute kidney injury. Ren Fail. 2014;36(10):1559–633.CrossRefPubMed Tu Y, et al. Urinary netrin-1 and KIM-1 as early biomarkers for septic acute kidney injury. Ren Fail. 2014;36(10):1559–633.CrossRefPubMed
Metadaten
Titel
Dynamic variation of kidney injury molecule-1 mRNA and protein expression in blood and urine of renal transplant recipients: a cohort study
verfasst von
Sanaz Keshavarz Shahbaz
Fatemeh Pourrezagholi
Mohesn Nafar
Pedram Ahmadpoor
Mehri Barabadi
Farshad Foroughi
Morteza Hosseinzadeh
Mir Saeed Yekaninejad
Aliakbar Amirzargar
Publikationsdatum
13.07.2019
Verlag
Springer Singapore
Erschienen in
Clinical and Experimental Nephrology / Ausgabe 10/2019
Print ISSN: 1342-1751
Elektronische ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-019-01765-y

Weitere Artikel der Ausgabe 10/2019

Clinical and Experimental Nephrology 10/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.